Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clindamycin.

D E Soper1

  • 1Department of Obstetrics and Gynecology, Medical College of Virginia, Virginia Commonwealth University, Richmond.

Obstetrics and Gynecology Clinics of North America
|September 1, 1992
PubMed
Summary
This summary is machine-generated.

Clindamycin is effective for obstetric and gynecologic infections, especially those caused by anaerobic bacteria. While rare, potential side effects like colitis are manageable with alternative treatments.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Necrotizing Fasciitis and Toxic Shock Syndrome from Clostridium septicum following a Term Cesarean Delivery.

Case reports in obstetrics and gynecology·2014
Same author

Urinalysis and urinary tract infection: update for clinicians.

Infectious diseases in obstetrics and gynecology·2002
Same author

Effectiveness of a rescue dose of antenatal betamethasone after an initial single course.

American journal of obstetrics and gynecology·2001
Same author

Scheduled cesarean delivery and the prevention of human immunodeficiency virus transmission: a survey of practicing obstetricians.

American journal of obstetrics and gynecology·2001
Same author

Hormonal and barrier contraception and risk of upper genital tract disease in the PID Evaluation and Clinical Health (PEACH) study.

American journal of obstetrics and gynecology·2001
Same author

Antibiotic resistance patterns of group B streptococci in late third-trimester rectovaginal cultures.

American journal of obstetrics and gynecology·2001
Same journal

Bridging Science and Practice in Gender-Affirming Care: A Compendium for Gynecologists.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evidence, Clinical Expertise, and Research Gaps in Gender-Affirming Care.

Obstetrics and gynecology clinics of North America·2026
Same journal

Evaluation and Management of the Pediatric Gender-Diverse Patient.

Obstetrics and gynecology clinics of North America·2026
Same journal

Expanding Access to Cervical Cancer Screening for Transgender and Nonbinary Individuals.

Obstetrics and gynecology clinics of North America·2026
Same journal

Updates on Breast Cancer Screening and Special Considerations for Transgender Men and Women.

Obstetrics and gynecology clinics of North America·2026
Same journal

Contraceptive Needs of the Transmasculine Patient.

Obstetrics and gynecology clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology and Infectious Diseases
  • Antimicrobial Therapy in Gynecology

Background:

  • Clindamycin has a 20-year history in treating obstetric and gynecologic infections.
  • It exhibits potent activity against anaerobic bacteria, including beta-lactamase-producing Bacteroides species.
  • Effective against aerobic gram-positive cocci like group B streptococci, but lacks activity against aerobic gram-negative rods (e.g., E. coli).

Purpose of the Study:

  • To review the established role and efficacy of clindamycin in obstetric and gynecologic infections.
  • To highlight its spectrum of activity, recommended dosage, and management of adverse effects.

Main Methods:

  • Review of clinical experience and established literature on clindamycin use.
  • Analysis of antimicrobial spectrum, particularly against key pathogens in pelvic infections.

Related Experiment Videos

  • Evaluation of standard treatment protocols and side effect management.

    • Main Results:

    • Clindamycin is a cornerstone in treating pelvic infections, often in combination with aminoglycosides.
    • A standard intravenous dose of 900 mg every 8 hours is recommended for severe infections.
    • Pseudomembranous colitis, though a concern, is rare and treatable with vancomycin or metronidazole.

    Conclusions:

    • Clindamycin remains a vital antibiotic for obstetric and gynecologic infections due to its anaerobic coverage.
    • Its efficacy and manageable side effect profile solidify its place in standard treatment regimens.
    • Clinicians should be aware of its specific antimicrobial spectrum and potential adverse events.